June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Correlation of Best Corrected Visual Acuity and Central Subfield Thickness in Macular Edema Due to Retinal Vein Occlusion, Diabetic Retinopathy and Uveitis
Author Affiliations & Notes
  • Dilraj Grewal
    Ophthalmology, Duke Eye Center, Durham, North Carolina, United States
  • Thomas A Ciulla
    Clearside Biomedical, Inc., Georgia, United States
    Indiana University School of Medicine, Indiana, United States
  • Barry Kapik
    Clearside Biomedical, Inc., Georgia, United States
  • Footnotes
    Commercial Relationships   Dilraj Grewal, Alimera (C), Clearside (C), DORC (C), EyePoint (C); Thomas Ciulla, Clearside Biomedical, Inc. (E), Clearside Biomedical, Inc. (I); Barry Kapik, Clearside Biomedical, Inc. (E), Clearside Biomedical, Inc. (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3239. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dilraj Grewal, Thomas A Ciulla, Barry Kapik; Correlation of Best Corrected Visual Acuity and Central Subfield Thickness in Macular Edema Due to Retinal Vein Occlusion, Diabetic Retinopathy and Uveitis. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3239.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Given the clinical importance of best corrected visual acuity (BCVA) and macular edema (ME) quantitated from OCT central subfield thickness (CST), this study assessed the relationship between BCVA and CST in ME due to retinal vein occlusion (RVO), diabetic retinopathy (DME) and noninfectious uveitis (NIU).

Methods : This post hoc analysis of eyes with ME due to RVO, DME, or NIU assessed the relationship between BCVA and CST in ME across three disease states, in 6 clinical trials, with monitor-verified diagnoses per eligibility criteria, Early Treatment Diabetic Retinopathy Study (ETDRS) protocol refractions and OCT reading center evaluation. Patients were assessed at monthly intervals for up to 6 months, independent of randomization to the active or control arm of the clinical trial. The two clinical trials for each of the thee disorders were analyzed separately and analyzed pooled by disorder. Correlation and univariate regression analyses were performed to assess relationships between ETDRS BCVA and CST.

Results : This analysis included 1,063 eyes with ME due to RVO (774 eyes), DME (91 eyes) and NIU (198 eyes). With respect to baseline BCVA and CST, Pearson Correlation Coefficients were: ME due to RVO -0.56 (95% CI -0.61 to -0.51, P <0.001), DME -0.50 (95% CI -0.64 to -0.33, P <0.001), and ME due to NIU -0.55 (95% CI -0.49 to -0.26, P <0.001). When correlating change from baseline to 6 months for both BCVA and CST, Pearson Correlation Coefficients were: ME due to RVO -0.35 (95% CI -0.43 to -0.27, P <0.001), DME -0.30 (95% CI -0.48 to -0.09, P =0.006), and ME due to NIU -0.40 (95% CI -0.53 to -0.29, P <0.001).

Conclusions : In this cohort of over 1000 eyes, there were moderate relationships between BCVA and CST in patients with ME due to RVO, DME and NIU at baseline and these were similar across disease states. There were also moderate relationships between BCVA and CST across these disease states with respect to change from baseline to 6 months. These correlations provide context around the use of CST in clinical decision making and visual recovery.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×